Hennion & Walsh Asset Management Inc. Sells 16,093 Shares of Grifols, S.A. (NASDAQ:GRFS)

Hennion & Walsh Asset Management Inc. reduced its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 6.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 244,151 shares of the biotechnology company’s stock after selling 16,093 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Grifols were worth $2,168,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GRFS. Capital World Investors raised its position in Grifols by 4.9% in the 1st quarter. Capital World Investors now owns 20,749,225 shares of the biotechnology company’s stock worth $138,605,000 after purchasing an additional 961,700 shares during the period. Brandes Investment Partners LP boosted its stake in shares of Grifols by 8.7% during the second quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock valued at $117,242,000 after purchasing an additional 1,481,924 shares during the period. Black Creek Investment Management Inc. grew its holdings in Grifols by 7.7% in the 2nd quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock worth $77,799,000 after acquiring an additional 881,155 shares during the last quarter. Armistice Capital LLC raised its stake in shares of Grifols by 18.7% during the second quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock valued at $49,759,000 after acquiring an additional 1,244,000 shares during the last quarter. Finally, Whitebox Advisors LLC boosted its holdings in shares of Grifols by 45.6% during the second quarter. Whitebox Advisors LLC now owns 2,702,390 shares of the biotechnology company’s stock worth $17,039,000 after purchasing an additional 846,940 shares during the period.

Grifols Trading Down 1.5 %

GRFS opened at $8.73 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.68 and a quick ratio of 0.80. The firm has a market capitalization of $6.00 billion, a price-to-earnings ratio of 8.56 and a beta of 0.50. The business has a 50 day simple moving average of $8.75 and a two-hundred day simple moving average of $7.73. Grifols, S.A. has a one year low of $5.30 and a one year high of $12.15.

Grifols (NASDAQ:GRFS) last announced its earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21). The firm had revenue of $1.96 billion for the quarter. Analysts predict that Grifols, S.A. will post 0.79 EPS for the current year.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.